Search details
1.
Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
Ann Oncol
; 2024 Apr 20.
Article
in English
| MEDLINE | ID: mdl-38648979
2.
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
Ann Oncol
; 34(4): 397-409, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36709040
3.
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.
Ann Oncol
; 34(8): 645-659, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37269905
4.
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.
Ann Oncol
; 33(5): 534-543, 2022 05.
Article
in English
| MEDLINE | ID: mdl-35182721
5.
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.
Ann Oncol
; 32(10): 1256-1266, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34384882
6.
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review.
Breast Cancer Res Treat
; 187(2): 323-337, 2021 Jun.
Article
in English
| MEDLINE | ID: mdl-34043122
7.
Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study.
Ann Oncol
; 31(10): 1359-1365, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32652112
8.
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer.
Breast Cancer Res Treat
; 183(2): 347-354, 2020 Sep.
Article
in English
| MEDLINE | ID: mdl-32621251
9.
Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning.
Semin Cancer Biol
; 52(Pt 2): 151-157, 2018 10.
Article
in English
| MEDLINE | ID: mdl-29990622
10.
Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.
Ann Oncol
; 30(12): 1941-1949, 2019 12 01.
Article
in English
| MEDLINE | ID: mdl-31566659
11.
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.
Ann Oncol
; 29(3): 646-653, 2018 03 01.
Article
in English
| MEDLINE | ID: mdl-29253081
12.
Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.
Breast Cancer Res Treat
; 167(1): 123-131, 2018 01.
Article
in English
| MEDLINE | ID: mdl-28929359
13.
Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.
Breast Cancer Res Treat
; 168(1): 169-178, 2018 Feb.
Article
in English
| MEDLINE | ID: mdl-29177605
14.
Neoadjuvant immunotherapy in triple-negative breast cancer: lesson learnt, remaining questions.
Ann Oncol
; 33(11): 1091-1093, 2022 11.
Article
in English
| MEDLINE | ID: mdl-36096335
15.
The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.
Ann Oncol
; 28(2): 321-328, 2017 02 01.
Article
in English
| MEDLINE | ID: mdl-28426105
16.
Improved prognosis of young patients with breast cancer undergoing breast-conserving surgery.
Br J Surg
; 104(13): 1802-1810, 2017 Dec.
Article
in English
| MEDLINE | ID: mdl-28791694
17.
Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer.
Ann Oncol
; 27(2): 249-56, 2016 Feb.
Article
in English
| MEDLINE | ID: mdl-26598540
18.
Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
Ann Oncol
; 26(4): 682-687, 2015 Apr.
Article
in English
| MEDLINE | ID: mdl-25600567
19.
The legacy of Professor Aron Goldhirsch.
Ann Oncol
; 31(6): 671-673, 2020 06.
Article
in English
| MEDLINE | ID: mdl-32217075
20.
Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy.
Ann Oncol
; 26(2): 307-13, 2015 Feb.
Article
in English
| MEDLINE | ID: mdl-25411418